Lys (CO-C3-p-I-Ph) -O-tBu

Lys (CO-C3-p-I-Ph) -O-tBu is a pharmacokinetic modifier (PK modifier) that can improve the pharmacokinetic properties of PSMA ligand molecules. Lys (CO-C3-p-I-Ph) -O-tBu can increase the residence time of PSMA ligand in plasma by increasing its binding capacity to albumin. Lys (CO-C3-p-I-Ph) -O-tBu also reduces salivary gland absorption, possibly extending the half-life of the active compound[1][2].

Product Specifications

CAS Number

[2703051-80-1]

UNSPSC

12352005

Target

DNA-PK

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/lys-co-c3-p-i-ph-o-tbu.html

Concentration

10mM

Purity

98.14

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

IC1=CC=C(CCCC(NCCCC[C@@H](C(OC(C)(C)C)=O)N)=O)C=C1

Molecular Formula

C20H31IN2O3

Molecular Weight

474.38

References & Citations

[1]Sun M, et al. Prostate-Specific Membrane Antigen (PSMA) -Targeted Radionuclide Therapies for Prostate Cancer. Curr Oncol Rep. 2021 Mar 29;23 (5) :59.|[2]Zitzmann-Kolbe S, et al., Preclinical evaluation of an actinium-225 labeled PSMA-targeting small molecule (225Ac-PSMA-Trillium (BAY 3563254) ) for the treatment of metastatic castration resistant prostate cancer (mCRPC) [J]. Cancer Research, 2024, 84 (6_Supplement) : 6033-6033.